[1]
|
Sun, X.L., Law, B.Y., de Seabra Rodrigues Dias, I.R., Mok, S.W.F., He, Y.Z. and Wong, V.K. (2017) Pathogenesis of Thromboangiitis Obliterans: Gene Polymorphism and Immunoregulation of Human Vascular Endothelial Cells. Athero-sclerosis, 265, 258-265. https://doi.org/10.1016/j.atherosclerosis.2017.08.009
|
[2]
|
Olin, J.W. (2000) Thromboan-giitis Obliterans (Buerger’s Disease). The New England Journal of Medicine, 343, 864- 869. https://doi.org/10.1056/NEJM200009213431207
|
[3]
|
Vijayakumar, A., Tiwari, R. and Kumar Prabhuswamy, V. (2013) Thromboangiitis Obliterans (Buerger’s Disease)- Current Practices. International Journal of Inflammation, 2013, Article ID: 156905.
https://doi.org/10.1155/2013/156905
|
[4]
|
Joviliano, E.E., Dellalibera-Joviliano, R., Dalio, M., Evora, P.R. and Pic-cinato, C.E. (2009) Etiopathogenesis, Clinical Diagnosis and Treatment of Thromboangiitis Obliterans—Current Practic-es. International Journal of Angiology, 18, 119-125. https://doi.org/10.1055/s-0031-1278337
|
[5]
|
Jorge, V.C., Araújo, A.C., Noronha, C., Panarra, A., Riso, N. and Vaz Riscado, M. (2011) Buerger’s Disease (Thromboangiitis Obliterans): A Diagnostic Challenge. BMJ Case Reports, 2011, bcr0820114621.
https://doi.org/10.1136/bcr.08.2011.4621
|
[6]
|
Shionoya, S. (1998) Diagnostic Criteria of Buerger’s Disease. In-ternational Journal of Cardiology, 66, S243-S245.
https://doi.org/10.1016/S0167-5273(98)00175-2
|
[7]
|
吕开平, 郭发才. 血栓闭塞性脉管炎的免疫相关性研究进展[J]. 血管与腔内血管外科杂志, 2018, 4(6): 556-560.
|
[8]
|
秦传子, 马军. NLRP3炎性小体在血栓闭塞性脉管炎发病机制中的作用研究进展[J]. 疑难病杂志, 2017, 16(4): 415-418.
|
[9]
|
Fazeli, B. and Ravari, H. (2014) A Dis-ease-Specific Activity Score for Thromboangiitis Obliterans. Vascular, 22, 336-340. https://doi.org/10.1177/1708538113516315
|
[10]
|
Akbarin, M.M., Ravari, H., Rajabnejad, A., Valizadeh, N. and Fazeli, B. (2016) Investigation of the Etiology of Anemia in Thromboangiitis Obliterans. International Journal of Angi-ology, 25, 153-158.
https://doi.org/10.1055/s-0035-1571190
|
[11]
|
Sena, C.M., Leandro, A., Azul, L., Seiça, R. and Perry, G. (2018) Vascular Oxidative Stress: Impact and Therapeutic Approaches. Frontiers in Physiology, 9, Article No. 1668. https://doi.org/10.3389/fphys.2018.01668
|
[12]
|
Marchio, P., Guerra-Ojeda, S., Vila, J.M., Aldasoro, M., Victor, V.M. and Mauricio, M.D. (2019) Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxi-dative Medicine and Cellular Longevity, 2019, Article ID: 8563845. https://doi.org/10.1155/2019/8563845
|
[13]
|
Senoner, T. and Dichtl, W. (2019) Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? Nutrients, 11, 2090. https://doi.org/10.3390/nu11092090
|
[14]
|
Ito, F., Sono, Y. and Ito, T. (2019) Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxi-dative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation. Antioxidants (Basel), 8, 72.
https://doi.org/10.3390/antiox8030072
|
[15]
|
Alamdari, D.H., Ravarit, H., Tavallaie, S. and Fazeli, B. (2014) Oxida-tive and Antioxidative Pathways Might Contribute to Thromboangiitis Obliterans Pathophysiology. Vascular, 22, 46-50. https://doi.org/10.1177/1708538112473979
|
[16]
|
伍慧丽, 时红波, 刘燕敏, 等. 性别差异对自身免疫性肝炎患者临床特征及预后的影响[J]. 临床肝胆病杂志, 2021, 37(7): 1636-1643.
|
[17]
|
Omoyinmi, E., Mohamoud, I., Gil-mour, K., Brogan, P.A. and Eleftheriou, D. (2018) Cutaneous Vasculitis and Digital Ischaemia Caused by Heterozygous Gain-of-Function Mutation in C3. Frontiers in Immunology, 9, Article No. 2524.
https://doi.org/10.3389/fimmu.2018.02524
|
[18]
|
Augusto, J.F., Langs, V., Demiselle, J., Lavigne, C., Brilland, B., Duveau, A., Poli, C., Chevailler, A., Croue, A., Tollis, F., Sayegh, J. and Subra, J.F. (2016) Low Serum Complement C3 Levels at Diagnosis of Renal ANCA-Associated Vasculitis Is Associated with Poor Prognosis. PLoS ONE, 11, e0158871. https://doi.org/10.1371/journal.pone.0158871
|
[19]
|
Fehérvári, M., Krepuska, M., Széplaki, G., Apor, A., Sótonyi, P., Prohászka, Z., Acsády, G. and Szeberin, Z. (2014) The Level of Complement C3 Is Associated with the Se-verity of Atherosclerosis But Not with Arterial Calcification in Peripheral Artery Disease. International Angiology, 33, 35-41.
|
[20]
|
Halacheva, K.S., Manolova, I.M., Petkov, D.P. and Andreev, A.P. (1998) Study of Anti-Neutrophil Cyto-plasmic Antibodies in Patients with Thromboangiitis Obliterans (Buerger’s Disease). Scandinavian Journal of Immunol-ogy, 48, 544-550.
|
[21]
|
Guo, Y., Dai, Y., Lai, J. and Fan, Y. (2013) Study about Correlation of Anti-Neutrophil Cyto-plasmic Antibodies and Anticardiolipin Antibodies with Thromboangiitis Obliterans. Vascular, 21, 363-368.
https://doi.org/10.1177/1708538113478742
|
[22]
|
Shanmugam, V.K., Angra, D., Rahimi, H. and McNish, S. (2017) Vasculitic and Autoimmune Wounds. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 5, 280-292. https://doi.org/10.1016/j.jvsv.2016.09.006
|
[23]
|
Chavoshan, A., Sharebiani, H., Taheri, H. and Fazeli, B. (2019) Antiphospholipid Antibodies in Buerger’s Disease. Thrombosis Research, 181, 64-66. https://doi.org/10.1016/j.thromres.2019.07.015
|
[24]
|
Undas, A., Nowakowski, T., Cieśla-Dul, M. and Sadowski, J. (2011) Abnormal Plasma Fibrin Clot Characteristics Are Associated with Worse Clinical Outcome in Patients with Pe-ripheral Arterial Disease and Thromboangiitis Obliterans. Atherosclerosis, 215, 481-486. https://doi.org/10.1016/j.atherosclerosis.2010.12.040
|
[25]
|
Raymackers, J.M. and Bosschaert, P. (2014) Cerebral Venous Thrombosis and Buerger’s Disease. Acta Neurologica Belgica, 114, 139-140. https://doi.org/10.1007/s13760-013-0237-z
|
[26]
|
Avcu, F., Akar, E., Demirkiliç, U., Yilmaz, E., Akar, N. and Yalçin, A. (2000) The Role of Prothrombotic Mutations in Patients with Buerger’s Disease. Thrombosis Research, 100, 143-147. https://doi.org/10.1016/S0049-3848(00)00310-8
|
[27]
|
Beigi, A.A., Hoghoughi, M.A., Eshaghian, A., Zade, A.H. and Masoudpour, H. (2014) The Role of Folic Acid on the Hyperhomocysteinemia in the Buerger’s Disease (Thromboangiitis Obliterans). Journal of Research in Medical Sciences, 19, 1034-1037.
|